Atomoxetine-induced myocardial infarction

Ali Seifi; Heidi Griffith; Sahar Avestimehr; Haitham Dib

doi:10.1097/SMJ.0b013e318205e575

Atomoxetine-induced myocardial infarction

Ali Seifi, Heidi Griffith, Sahar Avestimehr, Haitham Dib

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.

Original language	English (US)
Pages (from-to)	153-154
Number of pages	2
Journal	Southern medical journal
Volume	104
Issue number	2
DOIs	https://doi.org/10.1097/SMJ.0b013e318205e575
State	Published - Feb 2011
Externally published	Yes

Keywords

atomoxetine
attention deficit hyperactivity syndrome
myocardial infarction

ASJC Scopus subject areas

General Medicine

Access to Document

10.1097/SMJ.0b013e318205e575

Cite this

@article{5b25c8cc22754a3084dd3d712f1ca3cc,

title = "Atomoxetine-induced myocardial infarction",

abstract = "Atomoxetine (Strattera{\textregistered}, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.",

keywords = "atomoxetine, attention deficit hyperactivity syndrome, myocardial infarction",

author = "Ali Seifi and Heidi Griffith and Sahar Avestimehr and Haitham Dib",

year = "2011",

month = feb,

doi = "10.1097/SMJ.0b013e318205e575",

language = "English (US)",

volume = "104",

pages = "153--154",

journal = "Southern medical journal",

issn = "0038-4348",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Atomoxetine-induced myocardial infarction

AU - Seifi, Ali

AU - Griffith, Heidi

AU - Avestimehr, Sahar

AU - Dib, Haitham

PY - 2011/2

Y1 - 2011/2

N2 - Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.

AB - Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.

KW - atomoxetine

KW - attention deficit hyperactivity syndrome

KW - myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=79251622284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251622284&partnerID=8YFLogxK

U2 - 10.1097/SMJ.0b013e318205e575

DO - 10.1097/SMJ.0b013e318205e575

M3 - Article

C2 - 21206410

AN - SCOPUS:79251622284

SN - 0038-4348

VL - 104

SP - 153

EP - 154

JO - Southern medical journal

JF - Southern medical journal

IS - 2

ER -

Atomoxetine-induced myocardial infarction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this